A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

NCT06391177 | Completed Phase 1 Results FDA Drug

• 1 other identifier: VONO-401
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily or vonoprazan 20 mg administered twice daily for 4 consecutive days.

Conditions

Erosive Esophagitis; Heartburn; Symptomatic Nonerosive Gasroesophageal Reflux Disease; Helicobacter Pylori Infection

Keywords

Healthy participants; Helicobacter pylori infection; Erosive Esophagitis; Symptomatic nonerosive gasroesophageal reflux disease; Heartburn; Breast milk; Lactating women

Outcome Measures

Primary Outcomes (5)

• Area Under Drug Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) Following the Morning Dose of Vonoprazan in Breast Milk

  AUC from time 0 to 24 hours post-dose, calculated as: the sum of the product of the concentration of the interval and the width of the interval.

  Pre-dose on Day 4, and at regularly scheduled intervals through 24 hours after the morning dosing (0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, and 18-24 hours).

• Maximum Drug Concentration (Cmax) of Vonoprazan in Breast Milk

  Maximum observed concentration after dosing.

  Pre-dose on Day 4, and at regularly scheduled intervals through 24 hours after the morning dosing (0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, and 18-24 hours).

• Minimum Drug Concentration (Cmin) of Vonoprazan in Breast Milk

  Minimum observed concentration after dosing.

  Pre-dose on Day 4, and at regularly scheduled intervals through 24 hours after the morning dosing (0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, and 18-24 hours).

• Average Drug Concentration (Cavg) of Vonoprazan in Breast Milk

  Average concentration, calculated as: AUC0-24/tau (tau=the difference between the end time of the last interval and dosing time).

  Pre-dose on Day 4, and at regularly scheduled intervals through 24 hours after the morning dosing (0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, and 18-24 hours).

• Time to Cmax (Tmax) of Vonoprazan in Breast Milk

  Time to maximum observed concentration (actual midpoint of the interval in which Cmax was observed).

  Pre-dose on Day 4, and at regularly scheduled intervals through 24 hours after the morning dosing (0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, and 18-24 hours).

Secondary Outcomes (4)

• Total Amount of Vonoprazan Excreted in Breast Milk

  Pre-dose on Day 4, and at regularly scheduled intervals through 24 hours after the morning dosing (0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, and 18-24 hours).

• Percentage of Vonoprazan Excreted in Breast Milk Relative to the Total Dose Received

  Pre-dose on Day 4, and at regularly scheduled intervals through 24 hours after the morning dosing (0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, and 18-24 hours).

• Estimated Infant Daily Dose of Vonoprazan

  Pre-dose on Day 4, and at regularly scheduled intervals through 24 hours after the morning dosing (0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, and 18-24 hours).

• Estimated Relative Infant Dose to the Total Maternal Dose Received of Vonoprazan

  Pre-dose on Day 4, and at regularly scheduled intervals through 24 hours after the morning dosing (0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, and 18-24 hours).

Study Arms (2)

Vonoprazan 20 mg Once Daily

EXPERIMENTAL

Participants will be administered once-daily doses of vonoprazan 20 mg for 4 consecutive days (Days 1 through 4).

Drug: Vonoprazan

Vonoprazan 20 mg Twice Daily

EXPERIMENTAL

Participants will be administered twice-daily doses of vonoprazan 20 mg for 4 consecutive days (Days 1 through 4).

Drug: Vonoprazan

Interventions

Vonoprazan DRUG

Oral tablet.

Vonoprazan 20 mg Once Daily; Vonoprazan 20 mg Twice Daily

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The participant is a healthy lactating woman at least 18 years of age at the time of signing the informed consent form (ICF).
• The participant has delivered a normal term infant (at least 37 weeks gestation) and has been breastfeeding or actively pumping breast milk for at least 4 weeks postpartum prior to the first dose.
• The participant is willing to not breastfeed or otherwise use her breast milk during administration of vonoprazan and until at least 5 days after the last dose of the study drug.
• The participant has confirmed that her breastfed infant is able to feed from a bottle.
• The participant agrees to collect all breast milk from pre-dose to 24 hours after the morning dose administration on Day 4, using an electric pump.
• The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at Screening.
• Participants of childbearing potential must use an acceptable method of birth control (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) or be surgically sterile (ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). All participants must have a negative pregnancy test at Screening and before the first dose of study drug (Baseline).
• The participant agrees to comply with all protocol requirements.
• The participant is able to provide written informed consent.

You may not qualify if:

• The participant has a positive pregnancy test at Screening or Baseline, is planning to become pregnant before, during, or within 4 weeks after participating in this study, or intends to donate ova during this time period, or is of childbearing potential and not using an effective contraceptive method.
• The participant has a history of breast implants, breast augmentation, or breast reduction surgery that significantly impacts breastfeeding or collection of milk from one or both breasts.
• The participant has signs or symptoms of mastitis or other condition that would prevent the collection of milk from one or both breasts.
• The participant has undergone prior esophageal and/or gastrointestinal surgeries that may affect study drug absorption.
• The participant has undergone surgery (other than cesarean section) within 30 days before the first dose of study drug.
• The participant has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at Screening.
• The participant has any other clinically significant findings on physical examination, clinical laboratory abnormalities, or ECG results that preclude participation in the study, as deemed by the investigator.
• The participant has used any prescription (excluding hormonal birth control) and/or over-the-counter medications (including cytochrome P450 3A4 inducers), including herbal or nutritional supplements, within 14 days before the first dose of study drug, and/or is expected to require any such medication during the course of the study until end of the Treatment Period. Use of multivitamins and acetaminophen (up to 2 g per day) is permissible.
• The participant has consumed grapefruit and/or grapefruit juice, Seville orange, or Seville orange-containing products (eg, marmalade) within 7 days before the first dose of study drug and/or is expected to be unable to abstain through the study.
• The participant is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
• The participant has a history of alcohol abuse or drug dependency within 12 months before the first dose of study drug.
• The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening, Baseline, or Day 4 (Check-in).
• The participant is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and during the study.
• The participant has a history of relevant drug and/or food allergies (ie, any significant food allergy that could preclude a standard diet in the clinical research unit).
• The participant has received study drug in another investigational study (including vonoprazan) within 30 days prior to start of the Screening Period.

Sponsors & Collaborators

• Phathom Pharmaceuticals, Inc.: lead

Study Sites (1)

PPD Development, LP

Las Vegas, Nevada, 89113, United States

Location

MeSH Terms

Conditions

Heartburn

Interventions

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine

Condition Hierarchy (Ancestors)

Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Phathom Medical Information
• Organization: Phathom Pharmaceuticals, Inc.

medicalinformation@phathompharma.com

1-888-775-7428

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 25, 2024
• First Posted: April 30, 2024
• Study Start: May 7, 2024
• Primary Completion: September 13, 2024
• Study Completion: September 19, 2024
• Last Updated: March 25, 2025
• Results First Posted: March 25, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)